Calico (company) facts for kids
 |
|
| Subsidiary | |
| Industry | |
| Founded | September 18, 2013 |
| Founders | Bill Maris, Arthur D. Levinson |
| Headquarters | U.S,
,
U.S.
|
|
Area served
|
Worldwide |
|
Key people
|
Arthur D. Levinson (CEO) |
| Parent | Google (2013–2015) Alphabet Inc. (2015–present) |
Calico Life Sciences LLC is a subsidiary of Alphabet Inc. and with a focus on biotechnology their goal is to increase the understanding of the biology that controls human aging, attempting to devise interventions that may enable people to lead longer and healthier lives.
History
Calico, short for the California Life Company, was announced on September 18, 2013, prior to Google's restructuring and was co-founded by former Genentech chairman and CEO Arthur D. Levinson. In Google's 2013 Founders Letter, Larry Page described Calico as a company focused on "health, well-being, and longevity." It was incorporated into Alphabet with Google's other sister divisions in 2015.
The Calico team has included a number of pioneering researchers in the field of ageing research, including members of the National Academy of Sciences, Cynthia Kenyon and Daniel E. Gottschling. Some of the company’s earliest employees included the geneticist David Botstein, and cancer drug developer Robert L. Cohen, MD., Eric Verdin, CEO of The Buck Institute for Research on Aging, served as a consultant to the Calico team.
At the end of 2017 and the beginning of 2018, Calico lost two top scientists; in December 2017 Hal Barron, MD, its head of R&D, left for GlaxoSmithKline, and in March 2018 chief computing officer Daphne Koller, who was leading their computational biology efforts, left to pursue a venture in applying machine learning techniques to drug design.
Partnerships
In September 2014, Calico and AbbVie announced an R&D collaboration focused on aging and age-related diseases such as neurodegeneration and cancer. Working together with AbbVie, Calico pursues discovery-stage research and development utilizing state-of-the-art technology and advanced computing capabilities. AbbVie provides scientific and clinical development support and lends its expertise to commercialization activities. To date, the companies have committed to invest more than $1 billion into the collaboration.
In 2015, the Broad Institute of MIT and Harvard announced a partnership with Calico to "advance research on age-related diseases and therapeutics", a further partnership also was announced with the Buck Institute for Research on Aging. Also in 2015, Calico announced a partnership with QB3 based on researching the biology of aging and identifying potential therapeutics for age-related diseases and one with AncestryDNA based on conducting research into the genetics of human lifespan.
In October 2023, Nature, a weekly British scientific journal, published preclinical research findings that showed ABBV-CLS-484, a PTPN2/N1 phosphatase inhibitor being co-developed by AbbVie and Calico, provokes a potent dual response in cancer and immune cells.
See also
In Spanish: Calico (empresa) para niños
- Verily
- Altos Labs
- SENS Research Foundation
- Human Longevity
- Life extension
